Core Insights - The academic seminar on May 16 focused on the shift in treatment strategies for nasal diseases from a "one-size-fits-all" approach to precision-targeted therapies, marking a significant advancement in the field of otolaryngology [1] - The launch of the first biological agent for chronic rhinosinusitis with nasal polyps and the only IL-4Rα antibody for seasonal allergic rhinitis, Suptikab, was a milestone in the treatment of these common type 2 inflammatory diseases [1] Group 1: Treatment Evolution - Professor Xu Yu from Wuhan University People's Hospital highlighted the transition from "one-size-fits-all" to "precision typing" in managing chronic rhinosinusitis with nasal polyps, emphasizing the need for targeted biological agents to control high recurrence rates driven by type 2 inflammatory factors [2] - The latest guidelines in China advocate for monoclonal antibodies targeting type 2 inflammation, which can significantly improve outcomes for patients with refractory and severe chronic rhinosinusitis with nasal polyps [2] Group 2: Clinical Efficacy of Suptikab - Suptikab, approved for seasonal allergic rhinitis in January 2025, is the only IL-4Rα antibody for this condition, addressing long-standing clinical challenges in symptom control [2] - Clinical data showed that 52% of patients experienced rapid relief from nasal congestion within 4 days of the first dose, and 94% achieved mild or resolved eye symptoms after two doses [2] Group 3: Expert Recommendations - The first expert opinion paper on the use of biological agents for chronic rhinosinusitis with nasal polyps was published in February 2025, recommending biological treatment for adults with severe cases not controlled by standard therapies [2] - Clinical studies indicated that Suptikab significantly reduced nasal polyp size, with 84% and 90% of patients achieving polyp reduction at 12 and 24 weeks, respectively, showcasing its advantages over other biological treatments [2] Group 4: Company Commitment - Dr. Chen Bo, CEO of Kangnuo, emphasized the company's commitment to patient benefit and innovation in drug development, marking the launch of Suptikab as a breakthrough in addressing clinical needs in autoimmune diseases [2] - The company aims to continue enhancing treatment options for type 2 inflammatory diseases, focusing on patient and clinical needs to contribute to global nasal disease treatment [2]

Core Viewpoint - The 2025 CSCO Guidelines Conference has introduced the 2025 edition of the CSCO Guidelines for the Diagnosis and Treatment of Primary Non-Small Cell Lung Cancer (NSCLC), highlighting the inclusion of Hansoh Pharmaceutical's Amelot (Ametinib Mesylate Tablets) as the first Chinese original third-generation EGFR-TKI to receive a Class I recommendation for consolidation therapy in EGFR mutation-positive stage III unresectable NSCLC patients after chemoradiotherapy [1][2][3] Group 1 - The new recommendation is based on positive results from the POLESTAR study, a nationwide, multicenter, randomized, double-blind, controlled phase III clinical trial assessing the efficacy and safety of Amelot in consolidation therapy for stage III unresectable NSCLC patients with EGFR mutations after chemoradiotherapy [2] - The mid-term analysis of the POLESTAR study, presented at the 2024 World Lung Cancer Conference, showed a median progression-free survival (mPFS) of 30.4 months for the Amelot group, compared to 3.8 months for the placebo group, indicating an 8-fold improvement and an 85% reduction in the risk of disease progression or death [2] - The POLESTAR study exclusively included Chinese patients, demonstrating the significant efficacy of original EGFR-TKIs for domestic patients and providing high clinical relevance for China [2] Group 2 - NSCLC accounts for approximately 85% of all lung cancer cases in China, with nearly one-third being locally advanced (stage III) NSCLC, highlighting the urgent need for more precise and effective treatment options [2] - The rapid development of third-generation EGFR-TKIs represents a significant advancement in targeted therapy, offering more treatment choices to improve the diagnosis and treatment levels of stage III unresectable NSCLC and enhance patient prognosis [2] - The inclusion of Amelot as a Class I recommendation for consolidation therapy in this context confirms its application potential and is expected to guide the development of precision diagnosis and treatment for NSCLC in China, ultimately benefiting patients [3]